Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission

Blood

Volumn 95, Issue 1, 2000, Pages 62-66

  Hochhaus, Andreas ^a   Reiter, Andreas ^b   Saußele, Susanne ^b   Reichert, Anja ^b   Emig, Michael ^b   Kaeda, Jaspal ^b   Schultheis, Beate ^b   Berger, Ute ^b   Shepherd, Patricia C A ^b   Allan, Norman C ^b   Hehlmann, Rüdiger ^b   Goldman, John M ^b   Cross, Nicholas C P ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 18744419356     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.1.62     Document Type: Article

References (29)

1. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350-1354.
2. Morgan GJ, Hughes T, Janssen JW, et al. Polymerase chain reaction for detection of residual leukaemia. Lancet. 1989;1:928-929.
3. Hughes T, Martiat P, Morgan G, Sawyers C, Witte ON, Goldman JM. Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet. 1990;335:50.
4. Hughes T, Janssen JWG, Morgan G, et al. False-positive results with PCR to detect leukaemia-specific transcript. Lancet. 1990;335:1037-1038.
5. Hughes T, Goldman JM. Improved results with PCR for chronic myeloid leukaemia. Lancet. 1990;336:812.
6. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993; 82:1929-1936.
7. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet. 1993;341:275-276.
8. Malinge MC, Mahon FX, Delfau MH, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol. 1992;82: 701-707.
9. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood. 1996; 87:1549-1555.
10. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-3081.
11. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-1397.
12. Hehlmann R, Heimpel H, Hasford J, et al. and the German CML Study Group. Randomized comparison of interteron-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064-4077.
13. Guilhot F, Chastang C, Michallet M, et al. for the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229.
14. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
15. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254-261.
16. Mahon FX, Faberes C, Reiffers J. Response to IFNα in myelogenous leukaemia. Lancet. 1996; 347:57-58.
17. Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920-1923.
18. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998;16:1526-1531.
19. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol. 1995;91: 126-131.
20. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
21. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850-858.
22. Reiter A, Skladny H, Hochhaus A, et al. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol. 1997;97:86-93.
23. Cross NCP, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma. 1993;11(suppl 1):39-43.
24. van Rhee F, Marks DI, Lin F, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia. 1995;9:329-335.
25. Clarkson B, Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia. 1993;7:1683-1721.
26. Morley A. Quantifying leukemia. N Engl J Med. 1998;339:627-629.
27. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;88:3118-3122.
28. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biological significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.
29. Reiter A, Marley SB, Hochhaus A, et al. BCR-ABL positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-α. Br J Haematol. 1998; 102:1271-1278.